Mr. Grubsztajn was appointed President and Chief Executive Officer of the corporation in September 2010. He recently led the Company’s $34.5 million financing in April 2011. Prior to this, he led MethylGene’s business development activities since 2005 with responsibilities that included executing licensing opportunities, corporate partnerships, strategic alliances and research collaborations. Mr. Grubsztajn played a lead role in out-licensing deals that together have generated more than US$100 million in cash for the Company. He led MethylGene’s 2006 US$272M cancer co-development and profit-share deal with Pharmion Corporation (now Celgene Corporation) and a second research collaboration with Pharmion worth up to $100M for the development of inhibitors targeting sirtuins for cancer. In addition, he secured a $55M research partnership with Otsuka Pharmaceuticals for ocular diseases. Prior to joining MethylGene, Mr. Grubsztajn was employed at Caprion Pharmaceuticals (now Caprion Proteomics) where he was involved in numerous technology out-licensing and in-licensing deals with pharmaceutical and biotechnology companies, as well as academia and governments. Mr Grubsztajn is a member of the Licensing Executives Society and has presented at several workshops. He has been a board or committee member of the Maimonides Geriatric Centre Foundation since 2001. In 2008, Mr. Grubsztajn was granted the Certified Licensing Professional designation from the Licensing Executives Society. He received his MBA and Law degrees from McGill University.

Dr. Besterman joined MethylGene in January 1997 and headed the Company’s research and development programs. He has over 25 years of drug discovery research and development experience in the pharmaceutical and biotechnology industries. Dr. Besterman previously served as Head, Oncology Research Section and later as Head, Department of Cell Biology and Member, Research Executive Committee at Glaxo Research Institute in Research Triangle Park, North Carolina. Dr. Besterman led a multi-disciplinary team of over 30 scientists and clinicians in the exploration, identification and early clinical development of Glaxo’s first anti-cancer compound, Lurtotecan (a topoisomerase I inhibitor). At MethylGene, Dr. Besterman has led the discovery, preclinical and clinical development of three anticancer compounds and one antifungal compound. Dr. Besterman has been a member of the National Cancer Institute’s Special Review Committee for Natural Product Drug Discovery and an external reviewer for the National Science Foundation. He is also on the external review board of the Biotechnology Research Institute of the National Research Council of Canada. He is a co-inventor of 25 United States patents and patent applications and 90 peer reviewed scientific publications. Dr. Besterman received a B.Sc. in Biology from the State University of New York, a Ph.D. in Physiology and Biophysics from the University of Vermont’s School of Medicine and completed his post-doctoral research at Pennsylvania State University’s Medical Center. Dr. Besterman currently lectures in the graduate biotechnology program at McGill University.

Dr. Humphrey joined MethylGene in 2012 and leads the development of the Company’s clinical programs. Previously she was Vice President, Global Development Lead, Immuno-Oncology at Bristol-Myers Squibb (NYSE: BMY). During her eight-year tenure at Bristol-Myers Squibb, Dr. Humphrey supervised a number of in-licensed and internal development programs including the Phase II – IV development of ipilimumab (YERVOY®), which achieved global approval for the treatment of metastatic melanoma in 2011. From 1997 until 2003 Dr. Humphrey held increasingly senior clinical development positions at Bayer (XETRA: BAYN), leading the IND filing and the development of the multiple kinase inhibitor sorafenib (Nexavar®), which subsequently achieved global approval for advanced renal cell carcinoma and hepatocellular carcinoma. Dr. Humphrey received her B.A. degree in biochemistry from Harvard University, her M.D. degree from Case Western Reserve University, and completed her Medical Residency at the Johns Hopkins Hospital. From 1992 until 1997 Dr. Humphrey worked at the U.S. National Cancer Institute (NCI), first as a Clinical Oncology Fellow and later as a Staff Physician/Scientist in the NCI’s HIV and AIDS Malignancy Branch.

Mr. Kepper joined MethylGene in October 2000 as Chief Financial Officer. He has over 25 years of financial, operational and accounting experience. He previously served 15 years at Smith & Nephew, most recently as Vice President, Finance of their German operations, which include Germany, Austria, Switzerland and Eastern Europe. Mr. Kepper has been Vice President, Finance and Chief Financial Officer as well as Treasurer and Secretary and member of the Board of Directors of Smith & Nephew Canada from 1989 to 1995 having been promoted from Controller. Mr. Kepper held other financial, accounting and controllership positions with Mallinkrodt Canada Inc. and Sommerville Belkin Industries Inc. Mr. Kepper holds B. Comm. and MBA degrees from Concordia University and is a Certified Management Accountant.

Mr. Walewicz joined MethylGene in 2011 as Vice President, Business and Corporate Development. He has over 17 years of finance, business development and marketing experience in the biopharma industry. Prior to joining MethylGene Mr. Walewicz was the Vice President, Special Projects at Paladin Labs Inc. (TSX:PLB), a specialty pharmaceutical company, and Chief Operating Officer of its Paladin Biosciences division. Previously Mr. Walewicz was a senior healthcare equity research analyst for several prominent North American healthcare investment banks, most recently as Executive Director, Institutional Equity Research at CIBC World Markets. Mr. Walewicz holds a B.A. in Economics and a B.Sc. in Biochemistry from Queen’s University, an M.B.A. from McGill University, and is a CFA Charterholder.